###begin article-title 0
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 123 128 <span type="species:ncbi:9606">Human</span>
Gene Expression Analysis of an EGFR Indirectly Related Pathway Identified PTEN and MMP9 as Reliable Diagnostic Markers for Human Glial Tumor Specimens
###end article-title 0
###begin p 1
Recommended by Zhumur Ghosh
###end p 1
###begin p 2
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 75 81 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 83 89 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17</italic>
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 255 261 255 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17</italic>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 431 435 431 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 505 509 505 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 721 725 721 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 844 848 844 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 853 857 853 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 870 874 870 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 879 883 879 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 1156 1160 1156 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1165 1169 1165 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 648 653 <span type="species:ncbi:9606">human</span>
In this study the mRNA levels of five EGFR indirectly related genes, EGFR, HB-EGF, ADAM17, PTEN, and MMP9, have been assessed by Real-time PCR in a panel of 37 glioblastoma multiforme specimens and in 5 normal brain samples; as a result, in glioblastoma, ADAM17 and PTEN expression was significantly lower than in normal brain samples, and, in particular, a statistically significant inverse correlation was found between PTEN and MMP9 mRNA levels. To verify if this correlation was conserved in gliomas, PTEN and MMP9 expression was further investigated in an additional panel of 16 anaplastic astrocytoma specimens and, in parallel, in different human normal and astrocytic tumor cell lines. In anaplastic astrocytomas PTEN expression was significantly higher than in glioblastoma multiforme, but no significant correlation was found between PTEN and MMP9 expression. PTEN and MMP9 mRNA levels were also employed to identify subgroups of specimens within the different glioma malignancy grades and to define a gene expression-based diagnostic classification scheme. In conclusion, this gene expression survey highlighted that the combined measurement of PTEN and MMP9 transcripts might represent a novel reliable tool for the differential diagnosis of high-grade gliomas, and it also suggested a functional link involving these genes in glial tumors.
###end p 2
###begin title 3
1. Introduction
###end title 3
###begin p 4
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 724 725 724 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
Glioblastoma multiforme is the most malignant brain tumor among astrocytic gliomas with a typical prognosis of about 12 months in spite of current therapeutic approaches that include neurosurgery followed by combined chemotherapy and radiotherapy [1]. Recently, the development of massive screening genome technologies, such as gene expression profiling, has prompted new attempts to the classification of glioblastoma subgroups on molecular basis in order to identify new diagnostic or prognostic tools. At present the search for potential molecular markers among aberrant signal transduction pathways in glioblastoma is actively exploited for the optimization of existing therapies or the development of innovative drugs [2]. However, the accomplishment of this ambitious task is severely hindered by the extreme heterogeneity of glioblastoma tumor samples and by the subsequent variability of possibly identified molecular markers. One way to overcome this limit could be represented by the concomitant analysis of the mRNA expression of several selected genes, already known to be functionally involved in the cellular malignant transformation. This analysis could highlight differences in gene expression levels among high-grade gliomas, or at the same time it could reveal relationships within glioma subtypes between the genes analyzed in order to improve their reliability as prognostic or diagnostic markers.
###end p 4
###begin p 5
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 523 524 523 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
The epidermal growth factor (EGF) receptor (EGFR or ErbB1) plays a pivotal role in cancer physiology because its activation, elicited by at least six different endogenous peptidergic EGF-like ligands, leads to the activation of intracellular signalling pathways that modulate cell proliferation, metastasis, and angiogenesis [3]. About 40%-50% of glioblastoma cases are characterized by EGFR gene amplification or overexpression, together with the expression of the mutated and constitutively active EGFR isoform EGFRvIII [3]. Upregulation of the EGFR pathway could also result from an increased availability of EGFR endogenous agonists belonging to the family of EGF-like growth factors.
###end p 5
###begin p 6
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 301 302 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 313 314 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 317 318 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</italic>
###xml 608 609 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 774 775 774 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">5</xref>
###xml 897 898 897 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">5</xref>
Heparin-binding epidermal growth factor (HB-EGF) acts as a potent proliferative agent in many different cell types via the activation of EGFR or the other EGF-like receptor ErbB4 [4]. HB-EGF is initially synthesized as the membrane-spanning protein proHB-EGF and then is proteolytically cleaved by "A Disintegrin And Metalloproteinase" (ADAM) family members that release the soluble form (sHB-EGF) in the extracellular space. The ADAM isoform responsible for this process appears to be cell type dependent, since in different experimental models ADAM 10, 12, and 17 have been involved in proHB-EGF shedding [3]. The overexpression of ADAM17, also named "tumor necrosis factor-alpha-converting enzyme" (TACE), seems to be involved in the malignant potential of cancer cells [5], and, notably, this metalloprotease modulates HB-EGF shedding and cell proliferation in U373-MG glioblastoma cell line [5].
###end p 6
###begin p 7
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">6</xref>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">7</xref>
###xml 745 746 745 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 834 835 834 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">6</xref>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
In the clinical practice only 10%-20% of glioblastoma patients respond to EGFR kinase inhibitors, and this poor response has been ascribed to a combination of EGFR overexpression and loss or mutation of the Phosphatase and TEN sin homolog deleted from chromosome 10 (PTEN) tumor suppressor protein [6]. The PTEN phosphatase reduces the levels of the second messenger phosphatidylinositol 3,4,5-triphosphate (PI3K) and regulates the activity of the downstream PI-3K/AKT- and mammalian target of rapamacyn- (mTOR-) dependent pathways [7]. Notably, PTEN functional loss or mutation is present in 60%-70% of high-grade gliomas and is associated with malignant phenotypic changes such as migration capability, probably by modulation of FAK activity [8]. Moreover, since PTEN loss appears to accelerate the formation of high-grade gliomas [6], it could potentially represent a valid candidate gene to discriminate between high- and low-grade gliomas.
###end p 7
###begin p 8
###xml 535 536 535 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">9</xref>
###xml 608 609 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">10</xref>
###xml 631 632 631 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">9</xref>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">12</xref>
One typical feature of glioblastoma is its high ability to disseminate and spread to distant brain areas. Proteases expressed by glioma cells appear to play a significant role in these processes because selective matrix metalloproteinases like MMP2 or MMP9 degrade the extracellular environment in order to facilitate tumor cell growth and migration. Expression of these proteases appears to increase with glioma grade and in vitro studies showed that modifications of their expression levels resulted in altered migratory properties [9]. Although some previous reports have examined the expression of EGFR [3], PTEN [10], HB-EGF [9], ADAM17 [11], and MMP9 [12] in astrocytoma samples, at present the transcriptional expression of these five EGFR pathway-related genes has not yet been simultaneously investigated in glioma.
###end p 8
###begin p 9
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17</italic>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 113 117 113 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 123 127 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
Therefore, in this study we have evaluated by quantitative Real-time PCR the expression of ADAM17, EGFR, HB-EGF, PTEN, and MMP9 mRNAs in a panel of glioblastoma and anaplastic astrocytomas specimens and cell lines, and we have finally compared them to normal control samples to ascertain whether these expression profiles might provide additional tools in glioma diagnosis and in tumor subtypes identification.
###end p 9
###begin title 10
2. Materials and Methods
###end title 10
###begin title 11
###xml 5 10 <span type="species:ncbi:9606">Human</span>
2.1. Human Biopsy Samples
###end title 11
###begin p 12
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">13</xref>
###xml 535 542 535 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 668 675 666 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 842 849 838 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3</xref>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
###xml 510 518 <span type="species:ncbi:9606">patients</span>
###xml 658 666 <span type="species:ncbi:9606">patients</span>
###xml 774 779 <span type="species:ncbi:9606">human</span>
Biopsy samples, obtained from Azienda Ospedaliera Universitaria di Parma (Parma, Italy) after informed consent of the patients, were placed in ice-cold Trizol reagent (Invitrogen, Paisley, UK) and immediately processed for RNA extraction. Sections of samples were independently histologically and morphologically evaluated by different neuropathologists and classified as grade IV (glioblastoma multiforme) or grade III (anaplastic astrocytoma), according to WHO guidelines [13]. Clinical data of glioblastoma patients are reported in Table 1, and they included 19 females and 18 males (age range 23-84 years, mean 57.8 +/- 13.3). The anaplastic astrocytoma patients (Table 2) included 7 males and 9 females (age 28-68, mean 50.7 +/- 13.9). Total RNA samples extracted from human postmortem normal brain (NB) cortical regions, as reported in Table 3, were purchased from Ambion (Foster City, Calif, USA): these included 2 females and 3 males (age range 50-71 years, mean 60.6 +/- 9.3).
###end p 12
###begin title 13
2.2. Cell Lines
###end title 13
###begin p 14
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">14</xref>
###xml 7 12 <span type="species:ncbi:9606">human</span>
###xml 196 201 <span type="species:ncbi:9606">Human</span>
###xml 267 274 <span type="species:ncbi:9606">patient</span>
###xml 440 447 <span type="species:ncbi:9606">patient</span>
Normal human astrocytes (NHAs) were purchased from Cambrex (East Rutherford, NJ, USA) and cultivated in the specific astrocyte AGM medium (Cambrex) according to the manufacturer's specifications. Human glioma cell line U138-MG, derived from a glioblastoma multiforme patient and widely employed, was purchased from ATCC (Rockville, Md, USA); PRT-HU2 cells, previously described [14], were analogously derived from a glioblastoma multiforme patient. U138-MG and PRT-HU2 cells were cultivated in D-MEM medium supplemented with 10% FBS, 100 units/mL penicillin, 0.1 mg/mL streptomycin, and 1% L-glutamine (Invitrogen, Paisley, UK).
###end p 14
###begin title 15
2.3. Real Time Quantitative PCR
###end title 15
###begin p 16
###xml 49 51 49 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">14</xref>
###xml 454 461 454 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab5">Table 5</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">14</xref>
###xml 656 660 656 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 662 668 662 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17</italic>
###xml 670 674 670 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 676 682 676 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 688 692 688 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
Total RNA was extracted as previously described [14] and accurately quantified using spectrophotometric and fluorimetric (Quant-it RNA Assay, Invitrogen) approaches. The gene-specific primers were designed using the "Primer3 input" software (), and their specificity was verified using the Primer-BLAST software (). GeneBank accession numbers of the five genes examined, their respective primer pairs sequences, and PCR products lengths were reported in Table 5. Quantitative Real-time PCR analysis was performed as previously described [14]. For the absolute quantification of specific cDNA, standard curves were derived using different concentrations of EGFR, ADAM17, MMP9, HB-EGF, and PTEN DNA-sequenced templates, prepared by reamplifying the PCR purified products obtained from Real-time PCR. The second derivative maximum method in the Light Cycler software was used to calculate the crossing point (Cp) value, and the concentrations of each specific cDNA were determined. All results were quantitative expressed in femtograms (fg) of cDNA, normalized to a total RNA input of 1 microgram.
###end p 16
###begin title 17
2.4. Statistical and Bioinformatics Analysis
###end title 17
###begin p 18
###xml 369 370 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 374 375 372 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 688 692 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 697 701 695 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
All results were expressed as mean +/- standard deviation of each biopsy specimens, assayed in duplicate. The Instat v.3 software (GraphPad Software Inc., Mass, USA) was used for the statistical analysis of differences in gene expression between groups by one-way ANOVA and for the analysis of correlations among gene expression profiles, using the Pearson coefficient r. A P-value less than .05 was considered statistically significant. The dendrogram and the classification tree analysis were performed using the Orange data mining software (). In particular, for the hierarchical clustering analysis, an Euclidean distance matrix was adopted. Statistical trends were obtained from the PTEN and MMP9 average quantitative expression within normal control, anaplastic astrocytoma, and glioblastoma multiforme diagnostic classes, using the Excel software with an exponential setting (Microsoft Word Package 2003, Redmond, Wash, USA).
###end p 18
###begin title 19
3. Results
###end title 19
###begin p 20
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">1 </xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">2 </xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">1 </xref>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">2</xref>
###xml 392 406 392 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17, HB-EGF</italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 502 507 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9,</italic>
###xml 634 638 634 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 698 706 698 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1</xref>
The mRNA expression of the investigated genes of glioblastoma multiforme and normal brain specimens were analytically reported in Tables 1  and 2  and depicted in Figures 1  and 2. On the basis of their expression patterns in glioblastoma and using the mean values of normal samples as cut-off, the investigated genes were roughly classified in three different subgroups, the first including ADAM17, HB-EGF, and PTEN, whose average levels in glioblastoma were below the controls, the second comprising MMP9, whose majority of values in glioblastoma specimens were higher than in controls and, finally, the last one constituted by the EGFR gene, displaying the widest variation and data dispersion (Figure 1).
###end p 20
###begin p 21
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17</italic>
###xml 109 110 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 204 210 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17</italic>
###xml 261 267 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 540 541 532 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The mRNA levels of ADAM17 metallo-protease in glioblastoma (mean 5.88 fg +/- 5.71) were significantly lower (P < .002) than in controls (14.51 fg +/- 3.15). In particular, in 33 out of 37 cases (89.19%), ADAM17 expression was lower than in control samples. For HB-EGF gene, although 31 out of 37 (83.78%) glioblastoma samples displayed mRNA levels lower than controls, statistical analysis revealed that the difference between controls (18.36 fg +/- 10.52) and glioblastoma specimens (10.96 fg +/- 10.13) was not statistically significant (P < .434).
###end p 21
###begin p 22
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 134 138 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 419 420 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
PTEN expression pattern showed statistically lower mRNA levels in all glioblastoma samples compared to controls. Notably, the highest PTEN expression level among all glioblastoma had a quantitative expression (15.05 fg) that was less than 50% of the mean controls values (33.91 fg), with a control normalized ratio ranging from 2.25 to 82.72 fg. As expected, there was a very high statistically significant difference (P < .0001) of PTEN mRNA expression between glioblastoma (3.86 fg +/- 3.15) and controls (33.91 fg +/- 18.44).
###end p 22
###begin p 23
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 317 321 317 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 395 396 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
MMP9 was overexpressed in the majority of glioblastoma specimens (72.22%) and, furthermore, in a subgroup of 24 cases (64.86%) the expression level was at least twofold higher than in controls, with a control normalized ratio within this subgroup ranging from 1.74 to 123.71 fg. However, the mean expression level of MMP9 mRNA in glioblastoma (5.11 fg +/- 8.78) was not significantly different (P = .238) from control samples (0.35 fg +/- 0.27).
###end p 23
###begin p 24
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGRF</italic>
###xml 310 314 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 412 416 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 468 469 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
EGFR mRNA transcript levels, due to their amplitude in expression, were arbitrarily divided into two glioblastoma subgroups. The former, ranging from 0.77 to 95.25 fg, included 25 samples (67.63%); the latter, had EGRF absolute quantitative values ranging from 150.97 to 2562.92 fg. All control samples showed EGFR expression values below 100 fg, with a mean value of 35.98 fg +/- 16.51. It was evident that for EGFR there was no statistically significant difference (P < .371) between glioblastoma (247.60 fg +/- 517.45) and control samples (35.98 fg +/- 16.52).
###end p 24
###begin p 25
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 161 165 161 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 396 400 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 583 587 583 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 592 596 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 621 629 621 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2 </xref>
###xml 648 656 648 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 796 800 796 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 897 898 895 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 974 975 972 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 986 990 984 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 1095 1096 1089 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1138 1139 1132 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1200 1201 1194 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1355 1359 1349 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1364 1368 1358 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 1465 1466 1459 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 97 103 <span type="species:ncbi:9606">Person</span>
Within glioblastoma samples, a highly statistically significant negative correlation (P < .0001; Person coefficient r = -0.776) was related to the expression of PTEN and MMP9; in a different manner, a statistically significant positive correlation (P < .05; Pearson coefficient, r = 0.9221) was scored for the same genes within the control samples. The inverse correlation found between PTEN and MMP9 mRNA expression in glioblastoma compared to control samples, prompted us to investigate whether this correlation was also detectable in other glioma grades of malignancy. Therefore, PTEN and MMP9 expression, reported in Table 2 and illustrated in Figure 2, was investigated in 16 histological confirmed anaplastic astrocytoma specimens, previously classified as WHO grade III. In these samples, PTEN mRNA normalized quantitation (29.72 fg +/- 31.62) was not significantly different from control (P = .792), but this value was significantly higher compared to glioblastoma (P < .0001). MMP9 expression (13.60 fg +/- 17.28) was neither significantly different from the control (0.35 fg +/- 0.27, P = .113) nor from glioblastoma specimens (P = .103). Notably, no statistically significant correlation (P = .709) was found between the mRNA levels of these two genes in anaplastic astrocytoma samples. Differently from glioblastoma, no inverse correlation in PTEN and MMP9 expression was found comparing anaplastic astrocytoma and control samples (Pearson coefficient, r = 0.127).
###end p 25
###begin p 26
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 222 229 222 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4</xref>
###xml 247 251 247 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 402 406 402 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 186 191 <span type="species:ncbi:9606">human</span>
Then, PTEN and MMP9 mRNA levels were comparatively examined in two different human established glioblastoma cell lines (PRT-HU2 and U138-MG) and in a primary culture of embryonic normal human astrocytes (NHA), as shown in Table 4. In these cells, PTEN mRNA levels were much variable comparing to MMP9 expression; similarly to the above examined control samples, normal astrocytes exhibited the highest PTEN expression.
###end p 26
###begin p 27
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">1</xref>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">2</xref>
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">3</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">4 </xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">10</xref>
###xml 456 460 456 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 465 469 465 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 556 564 556 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 846 854 846 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 925 929 925 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 934 938 934 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 950 952 950 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">; </italic>
###xml 1111 1115 1111 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1120 1124 1120 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 1198 1199 1198 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">1</xref>
###xml 1200 1201 1200 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">3</xref>
###xml 1458 1459 1458 1459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1536 1540 1536 1540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1545 1549 1545 1549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 1083 1091 <span type="species:ncbi:9606">patients</span>
###xml 1216 1224 <span type="species:ncbi:9606">patients</span>
###xml 1351 1359 <span type="species:ncbi:9606">patients</span>
###xml 1659 1667 <span type="species:ncbi:9606">patients</span>
We next exploited if PTEN and MMP9 expression might be more tightly related to the glioma tumor progression. To this purpose, different bioinformatics analyses were performed using the experimental data set reported in Tables 1, 2, 3, and 4  and considering the WHO grading of the specimens. We therefore performed hierarchical clustering, a standard unsupervised learning method [10] of the tumor specimens. The WHO grading was simultaneously compared to PTEN and MMP9 expression values, to identify homogeneous clusters. As reported in the dendrogram of Figure 3, different groups of samples were created, according to the above mentioned criteria. Using Euclidean distances, WHO grades IV and III and normal control samples were roughly classified into different clusters. Of note, a major subset of the glioblastoma specimens was identified (Figure 3, subgroup IV-a), showing the lowest and almost similar levels of both PTEN and MMP9 transcripts; the remaining glioblastoma samples clustered within subgroup IV-b. The association of tumor anatomical localization and age of the patients with the levels of PTEN and MMP9 expression was also investigated. According to the clinical data (Tables 1-3), ages of the patients were divided into three classes (i.e., I, 20-40; II, 41-60; III, >61 years): as reported in the dendrogram, the age-class III patients exhibited a statistically significant difference in distribution between subgroups IV-a and IV-b (P < .01, Anova one-way). Differently, no clear associations between levels of PTEN and MMP9 expression and tumor localization were highlighted, with the exception of a single cluster of four class-III patients with a temporal tumor localization within subgroup IV-a.
###end p 27
###begin p 28
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 81 85 81 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 181 189 181 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4</xref>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 418 419 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 538 539 538 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 566 570 566 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 664 667 664 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 713 714 713 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Then, a classification tree was produced, evaluating the performance of PTEN and MMP9 expression in predicting roots characterized by different WHO malignant grades; as reported in Figure 4, 53 out of 58 total samples, corresponding to 53 instances (i.e., 91.3%) fitted with the classification tree; in detail, all grade IV samples had PTEN normalized expression values below a quantity of 19.195 fg (37/37 instances, P = .905), while the large majority of control (80% of the total C instances) and anaplastic astrocytomas samples (70%, P = .636) were grouped with PTEN > 19.195 fg; in this subgroup, to further differentiate control and anaplastic astrocytomas, MMP9 < 0.775 fg clustered all control instances (P = 1.000).
###end p 28
###begin p 29
###xml 70 79 70 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5 </xref>
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 245 246 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 246 257 246 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(grade III)</sub>
###xml 323 327 323 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 539 540 539 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 540 549 540 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(control)</sub>
###xml 560 561 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 561 571 561 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(grade IV)</sub>
Nomogram analysis, performed within the same data set and reported in Figure 5 confirmed that PTEN and MMP9 expression analysis might be particularly helpful in the identification of anaplastic astrocytoma specimens having a 95% of probability (P(grade III) = .95) to correctly classify these samples, in correspondence of MMP9-normalized expression value of 19.195 fg, independently of PTEN expression level. Nomograms analysis with control and glioblastoma as target diagnostic classes showed less statistical significant probabilities (P(control) = .60 and P(grade IV) = .55).
###end p 29
###begin p 30
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 240 248 240 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6</xref>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 305 309 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 529 538 529 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6 </xref>
###xml 662 666 662 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 671 675 671 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 808 812 808 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 817 821 817 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 901 905 901 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 910 914 910 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 608 613 <span type="species:ncbi:9606">human</span>
###xml 774 781 <span type="species:ncbi:9606">patient</span>
To further elucidated if PTEN and MMP9 expression had an expression trend that reflected the malignant grade of the specimens (i.e., normal, anaplastic astrocytomas, and glioblastoma multiforme), a statistical trend analysis was performed (Figure 6); the analysis reported in Panel A showed that PTEN and MMP9 differences in their normalized expression clearly decreased following the malignant glioma grading, with the lowest values corresponding to glioblastoma multiforme specimens; similarly, the trend analysis, reported in Figure 6 Panel B, highlighted that, within the investigated cell lines, normal human astrocytes exhibited the largest differences in PTEN and MMP9 expression levels, while, on the contrary, U138-MG cells, isolated from a glioblastoma multiforme patient, showed nearly coincident PTEN and MMP9 expression values; the glioblastoma derived PRT-HU2 cell line showed values of PTEN and MMP9 expression trends, intermediate between NHA and U138-MG.
###end p 30
###begin title 31
4. Discussion
###end title 31
###begin p 32
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 563 567 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 817 824 817 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM-17</italic>
###xml 826 830 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 832 836 832 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 838 842 838 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 848 854 848 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 883 887 883 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 1217 1219 1217 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
The new challenge in cancer biology is to move from one purely morphological classification of cancer to one that is based on the integration of histological and molecular criteria [15]. Among several cancer specific investigated genes, the epidermal growth factor receptor (EGFR) plays a pivotal pathological role through the activation of downstream intracellular signalling pathways that can directly modulate cell proliferation, metastasis, and angiogenesis [8]. Glial tumors, in particular, due to processes of gene-amplification or mutation, showed altered EGFR-related functional pathways [3]. Within this context, in order to find clinically relevant correlations between gene expression and tumor malignant progression, a cohort of glioma specimens was analyzed for the expression of several genes, that is, ADAM-17, PTEN, MMP9, EGFR, and HB-EGF, indirectly involved in the EGFR-dependent signaling pathway, In fact, the concurrent measurement of the transcript levels of the different genes could potentially represent a useful tool to identify a dysregulation of receptor activation or of downstream signaling pathways or might also suggest functional links between these genes in pathological conditions [16].
###end p 32
###begin p 33
###xml 73 82 73 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">, ADAM-17</italic>
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 311 315 311 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 317 323 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 406 410 406 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 611 615 611 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 786 790 786 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 795 803 795 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFRvIII</italic>
###xml 832 836 832 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
Comparing a cohort of glioblastoma specimens and controls, only two genes, ADAM-17 and PTEN, had expression levels that significantly changed between the two WHO classes; on the contrary, considering the expression of each transcript separately, we did not elucidate any association between clinical status and EGFR, HB-EGF, and MMP9 expression profiles. In particular, the wide range of variation for the EGFR gene, found in glioblastoma specimens, was in partial agreement with previous studies carried out in glial tumor samples [8]. In general, nearly 50% of glioblastoma multiforme cases express amplified EGFR, and about 40% of them also express the constitutively activated mutated EGFRvIII isoform [11]. Since the primers we used in our experiments did not discriminate between EGFR and EGFRvIII, it is very likely that the EGFR mRNA levels found in our samples reflected the combined contribution of both the transcripts.
###end p 33
###begin p 34
###xml 98 104 98 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">17</xref>
###xml 188 194 188 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 280 288 280 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFRvIII</italic>
###xml 301 307 301 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">18</xref>
###xml 539 545 539 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">9</xref>
###xml 644 650 644 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 806 812 806 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">19</xref>
Since chemotherapic treatments enhance the EGFR-mediated proliferative responses via an increased HB-EGF expression and shedding [17], previous studies have suggested a prominent role for HB-EGF in tumorigenic processes. In fact, in glioma cell lines, the inducible expression of EGFRvIII can enhance HB-EGF expression and can activate EGFR-dependent pathways via a positive feedback autocrine loop [18]. The only previous published study, based on a semiquantitative assessment by Northern blot analysis, found an increased expression of HB-EGF in glioblastoma compared to control samples [9]. On the opposite, our data seemed to suggest that HB-EGF is not upregulated in glioblastoma; however, our results agreed with microarray gene expression profiles studies that showed no significant differences in HB-EGF expression between glioblastoma and control samples [19].
###end p 34
###begin p 35
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">12</xref>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 389 393 389 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">12</xref>
Recent mounting evidence showed that the expression of MMP9 might play a critical role in brain neoplastic tissue invasion, metastasis, and angiogenesis [12]. Even if not completely statistically supported, our findings were in good agreement with a previous work showing an upregulation of MMP9 mRNA levels in glioblastoma compared to controls and suggesting a close relationship between MMP9 expression and tumor malignant progression [12].
###end p 35
###begin p 36
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17</italic>
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">5</xref>
###xml 317 323 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17</italic>
###xml 345 354 345 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">proHB-EGF</italic>
###xml 370 374 370 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">5</xref>
###xml 409 415 409 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17</italic>
###xml 566 572 566 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17</italic>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">20</xref>
###xml 55 60 <span type="species:ncbi:9606">human</span>
Although ADAM17 expression has been reported in normal human brain tissue and in cell lines [5], its expression at mRNA level has been poorly investigated in brain tumors. Functional studies in U373-MG glioma cells have demonstrated that cannabinoids induced cell proliferation through a two-step mechanism involving ADAM17-mediated shedding of proHB-EGF and subsequent EGFR stimulation [5]. Our finding that ADAM17 mRNA levels in glioblastoma are statistically lower compared to controls is in contrast with a previous work that reported an increased expression of ADAM17 in glioblastoma specimens [20]. This might reflect differences in tumor sampling or a consequence of glioblastoma multiforme cellular and molecular heterogeneity.
###end p 36
###begin p 37
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">21</xref>
###xml 171 175 171 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 409 413 409 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 682 685 682 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nf1</italic>
###xml 690 693 690 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 730 734 730 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 827 828 827 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">6</xref>
###xml 625 630 <span type="species:ncbi:10090">mouse</span>
Our finding showing that glioblastoma expressed statistically significant lower PTEN mRNA levels compared to control samples confirmed previous reports [21], showing that PTEN expression variations were detectable only in a low fraction of anaplastic astrocytoma and were almost absent in low-grade brain tumors and controls. Taken together, these observations strengthen the hypothesis that an impairment of PTEN expression, together with a consequent aberrant activity of the PI3K-dependent pathway, might represent a typical hallmark of glioblastoma multiforme. A functional confirmation of this hypothesis was that, in a mouse astrocytoma model with genetic inactivation of the Nf1 and p53 tumor suppressor genes, the loss of PTEN heterozygosity and the Akt activation contributed to the brain tumor malignant progression [6].
###end p 37
###begin p 38
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 565 569 565 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 574 578 574 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 873 877 873 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 882 886 882 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 1077 1081 1077 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1082 1086 1082 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 1470 1472 1470 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">22</xref>
###xml 1495 1499 1495 1499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1504 1508 1504 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 1656 1660 1656 1660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1665 1669 1665 1669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 2039 2043 2039 2043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 2048 2052 2048 2052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 2225 2229 2225 2229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 2234 2238 2234 2238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 2596 2598 2596 2598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">23</xref>
###xml 2600 2602 2600 2602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">24</xref>
###xml 440 447 <span type="species:ncbi:9606">patient</span>
###xml 656 664 <span type="species:ncbi:9606">patients</span>
###xml 771 779 <span type="species:ncbi:9606">patients</span>
###xml 953 961 <span type="species:ncbi:9606">patients</span>
###xml 1021 1029 <span type="species:ncbi:9606">patients</span>
###xml 1352 1359 <span type="species:ncbi:9606">patient</span>
Differently from the above mentioned investigated genes, the analysis of PTEN and MMP9 expression, using a combination of unsupervised and supervised algorithms, provided interesting results: firstly, as reported in the dendrogram analysis, the expression profiling derived novel subsets of astrocytomas. This hierarchically clustering analysis clarified that tumor classification based even on a quantization of two genes could generate a patient stratification, clinically relevant and more informative than a single conventional histological classification. The PTEN and MMP9 expression-generated subgroups produced also a different distribution of the patients according to their age: in particular subgroup IV-a, differently from IV-b, was enriched in age-class III patients (i.e., >61 years); this result might suggest that in glioblastoma multiforme tumor specimens PTEN and MMP9 expression levels might be partly related with the elderly of the patients. On the contrary, in anaplastic astrocytoma and in control patients no association between age-related classes and PTEN/MMP9 expression levels was evidenced. Furthermore, the originated dendrogram does not reflect a classification of samples according to their anatomical tumor localization. However, in the light of the development of new pharmacological treatments, the identification of patient subsets with specific molecular signatures within tumor malignancy grades is becoming more and more relevant [22]. A finer analysis of PTEN and MMP9 expression was also employed to derive a parsimonious classification tree of the investigated samples into their tumor malignancy grades. Specific PTEN and MMP9 expression values significantly addressed the specimens into a specific diagnostic class, that is, glioblastoma or anaplastic astrocytomas. However, the significance and the sensitivity of this classification might be further refined with the increasing of specimens and through the identification of novel tumor-diagnostic markers. Basing on the average expression of PTEN and MMP9, the observed statistical trends clearly differentiate the control, anaplastic astrocytomas, and glioblastoma multiforme diagnostic classes; a similar expression trend for PTEN and MMP9 genes was documented comparing normal versus astrocytic tumor cell lines. These results, in particular, reinforced the concept that anaplastic astrocytomas were intermediate-grade tumors, showing detectable mitotic activity, absent in low-grade astrocytomas, but not necrosis and prominent vascular proliferation, characteristic of glioblastoma multiforme [23, 24].
###end p 38
###begin p 39
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 539 543 539 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 590 594 590 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 599 603 599 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 665 669 665 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 702 706 702 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 979 983 979 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 988 992 988 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1103 1107 1103 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1208 1209 1208 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">9</xref>
###xml 1211 1213 1211 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">25</xref>
###xml 1289 1293 1289 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1349 1351 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">26</xref>
###xml 1400 1404 1400 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1729 1733 1729 1733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1743 1747 1743 1747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
An additional interesting finding emerging from our study was the significant negative correlation between PTEN and MMP9 mRNA expression in glioblastoma multiforme. Notably, not only was this negative correlation absent in anaplastic astrocytoma samples, but it was reversed in control samples. It was evident that differences in PTEN gene expression mainly account for these correlations because its levels in glioblastoma were significant higher compared to anaplastic astrocytoma samples, whilst no statistical difference was found for MMP9 mRNA levels. The positive correlation between PTEN and MMP9 in controls is derived essentially from an overexpression of PTEN rather than a low expression of MMP9 compared to glioblastoma. The functional significance of these correlations is currently unknown, and future functional studies aimed at elucidating possible interplays of these genes in glioblastoma are clearly warranted. The negative correlation in glioblastoma between MMP9 and PTEN could imply a functional interplays between these two genes, as already documented. It has been reported that PTEN modulates the expression and secretion of MMP2 and MMP9, thereby modifying tumor cell invasiveness [9, 25]. Notably, recent reports have clearly demonstrated that, in glioblastoma, PTEN may regulate migration via a PI3K-independent pathway [26]. In this model, the lack or functional loss of PTEN not only potentiates the migration induced by EGFR- and beta-integrin-dependent pathways but also enhances cell migration via a still largely unclear mechanism. On this regard, a recent report suggested that integrins could be a converging point in the mechanism supporting tumor invasion and migration of cancer cells with PTEN loss and MMP9 overexpression.
###end p 39
###begin p 40
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 546 550 546 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 560 564 560 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 645 649 645 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 974 975 974 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">7</xref>
###xml 1010 1014 1010 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 1019 1023 1019 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 1424 1426 1424 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">27</xref>
###xml 1710 1712 1710 1712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1676 1681 <span type="species:ncbi:9606">human</span>
The intrinsic genetic heterogeneity and redundant overlapping aberrant signalling transduction pathways underlie the failure of monotherapies in glioblastoma [8]. Therefore a sensitive and reliable method to measure gene expression, such as Real-time PCR, may greatly ameliorate diagnostic tools and eventually address the pharmacological approach using multitarget kinase inhibitors or combination of therapies based on multiple single-targeted receptor or intracellular kinase inhibitors. Some researchers have proposed that the combination of PTEN loss and EGFR hyperfunctionality could be predictive of the ineffectiveness of therapies with EGFR inhibitors [4] because these two pathways might synergize to enhance glioblastoma malignancy. This hypothesis has been elegantly supported by the recent observation that the pharmacological inhibition of PI3K-alpha and mTOR augments the antiproliferative activity of the EGFR inhibitor erlotinib in glioblastoma cell lines [7]. The inverse correlation between PTEN and MMP9 expression reported here raised the issue whether the concomitant hyperactivation of the PI3K-alpha and MMP9-dependent pathways might be instrumental in devising or refining combined pharmacological therapies in glioblastoma. The modest efficacy of mTOR inhibitors alone in clinical trials was greatly enhanced when these compounds were administered in combination with the EGFR inhibitor Gefitinib [27]. Although monotherapy regimens with MMPs inhibitors in clinical trials have been quite disappointing, the relevance of MMPs as valid target has been reevaluated by the recent finding that the combined use of MMPs, COX2, and EGFR inhibitors reduced human breast cancer tumor growth [11]. We therefore speculate that the pivotal role of MMPs in glioma invasion and angiogenesis deserves future in vitro and in vivo experiments using MMP inhibitors in combination with PI3K inhibitors alone or with these latter compounds plus EGFR inhibitors.
###end p 40
###begin p 41
###xml 1197 1199 1197 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">28</xref>
###xml 1332 1334 1332 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">29</xref>
###xml 1459 1461 1459 1461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">30</xref>
###xml 1484 1495 1484 1495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH, ACTB</italic>
###xml 1501 1505 1501 1505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HPRT</italic>
The analyses of gene expression at transcriptional level in biopsy tissue samples are instrumental in delineating abnormal gene expression signature of brain tumors, but it should be mentioned that these studies suffer some pitfalls and limitations: in particular, the use of supervised approaches, based on the assumption that the grouping (i.e., the histological tumor diagnoses) is correct, may not be a valid assumption for all the clinical cases examined; additionally, the intrinsic heterogeneity of glioblastoma, together with the presence of nontumor cells in the samples, probably accounts for the variability found in transcripts levels and may represent a critical factor and a limitation in the interpretation of our results. From a technical point of view, a main difference of our contribution, compared to other reports, deals with the criteria adopted to express transcript levels in the investigated specimens. The majority of clinical gene expression profile studies performed by Real-time PCR normalized data using an internal housekeeping gene as a reference, but great caution in choosing this normalization method is necessary especially when analyzing tumor biopsy samples [28]. The tumorigenic process itself, via genomic mutations or amplifications, could induce modifications of housekeeping genes levels [29], and hence the choice of unreliable housekeeping genes may lead to interpretation errors and bias in experimental results [30]. Our attempts to use GAPDH, ACTB, and HPRT as reference genes were unsuccessful due to the great variations among all the samples (data not shown); therefore, we decided to express gene expression as absolute amount of femtograms (fg) of transcripts, normalized to the total amount of RNA employed, through accurate quantification using the combination of spectrofotometric and fluorimetric approaches.
###end p 41
###begin p 42
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 282 286 282 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 162 167 <span type="species:ncbi:9606">human</span>
###xml 393 398 <span type="species:ncbi:9606">human</span>
In conclusion, the combined analysis of the transcripts of PTEN and MMP9 genes in biopsy specimens could represent a reliable diagnostic and prognostic marker of human glial tumor. Further epidemiological and functional in vitro studies are required to establish the reliability of PTEN and MMP9 genes as possible valid molecular targets in the pharmacological strategies aimed at controlling human glioma malignant progression.
###end p 42
###begin title 43
Acknowledgments
###end title 43
###begin p 44
This study was supported by grants from the Italian MIUR, "Progetti di Ricerca di Rilevante Interesse Nazionale (2005)." A. A. is granted by Fondo Sociale Europeo (F.S.E.). The authors are particularly grateful to Dr. Eugenio Benericetti (Azienda Ospedaliera di Parma, Italy) for providing WHO graded glioma specimens. Orange Software is released under General Programming License (GPL). The authors are therefore particularly grateful to Orange Program's authors, Demsar J, Zupan B, Leban G: (2004) Orange: From Experimental Machine Learning to Interactive Data Mining, White Paper (), Faculty of Computer and Information Science, University of Ljubljana (Slovenia).
###end p 44
###begin article-title 45
Molecular pathology of malignant gliomas
###end article-title 45
###begin article-title 46
Genetic pathways to primary and secondary glioblastoma
###end article-title 46
###begin article-title 47
ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk
###end article-title 47
###begin article-title 48
Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy
###end article-title 48
###begin article-title 49
###xml 72 77 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor
###end article-title 49
###begin article-title 50
Pten haploinsufficiency accelerates formation of high-grade astrocytomas
###end article-title 50
###begin article-title 51
###xml 33 38 33 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma
###end article-title 51
###begin article-title 52
Targeting the EGFR pathway for cancer therapy
###end article-title 52
###begin article-title 53
###xml 113 118 <span type="species:ncbi:9606">human</span>
Hyaluronic acid induces osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to enhance the motility of human glioma cells
###end article-title 53
###begin article-title 54
Supervised harvesting of expression trees
###end article-title 54
###begin article-title 55
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
###end article-title 55
###begin article-title 56
###xml 77 82 <span type="species:ncbi:9606">human</span>
Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas
###end article-title 56
###begin article-title 57
Expression of endothelins and their receptors in glioblastoma cell lines
###end article-title 57
###begin article-title 58
Glioma classification: a molecular reappraisal
###end article-title 58
###begin article-title 59
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme
###end article-title 59
###begin article-title 60
Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance
###end article-title 60
###begin article-title 61
Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells
###end article-title 61
###begin article-title 62
Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis
###end article-title 62
###begin article-title 63
###xml 72 77 <span type="species:ncbi:9606">human</span>
Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness
###end article-title 63
###begin article-title 64
Pten signalling in gliomas
###end article-title 64
###begin article-title 65
###xml 28 33 <span type="species:ncbi:9606">human</span>
Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets
###end article-title 65
###begin article-title 66
Molecular pathogenesis of astrocytic tumours
###end article-title 66
###begin article-title 67
Molecular pathogenesis of malignant gliomas
###end article-title 67
###begin article-title 68
###xml 56 61 <span type="species:ncbi:9606">human</span>
PTEN gene transfer suppresses the invasive potential of human malignant gliomas by regulating cell invasion-related molecules
###end article-title 68
###begin article-title 69
Regulation of cell migration by the C2 domain of the tumor suppressor PTEN
###end article-title 69
###begin article-title 70
Molecularly targeted therapy for malignant glioma
###end article-title 70
###begin article-title 71
###xml 144 149 <span type="species:ncbi:9606">human</span>
Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies
###end article-title 71
###begin article-title 72
De-regulation of common housekeeping genes in hepatocellular carcinoma
###end article-title 72
###begin article-title 73
Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR
###end article-title 73
###begin p 74
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADAM17</italic>
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HB-EGF</italic>
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 217 218 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 93 98 <span type="species:ncbi:9606">human</span>
The mRNA expression levels of (a) ADAM17, (b) HB-EGF, (c) PTEN, (d) MMP9, and (e) EGFR in 37 human glioblastoma samples (GBM) and in five normal brain cortex samples (NB). Horizontal lines represent the mean values. *P < .002, **P < .0001. 
###end p 74
###begin p 75
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 50 55 <span type="species:ncbi:9606">human</span>
The mRNA expression levels of PTEN and MMP9 in 16 human grade III astrocytoma samples (AA). Bold horizontal lines represent the mean values, and thin lines represent the mean normal brain cortex samples (NB) values. 
###end p 75
###begin p 76
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 608 609 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
###xml 587 595 <span type="species:ncbi:9606">patients</span>
Dendrogram comparing PTEN and MMP9 absolute quantitative expression. Absolute quantifications are expressed in femtograms, as reported in Materials and Methods. WHO grades of malignancy (III, IV) and healthy brain control (C) specimens are indicated. Glioblastoma multiforme subgroups IV-a, including the majority of glioblastoma specimens, and IV-b, described in Results, are highlighted. The box (*) indicates subgrouping of patients sharing similar tumor anatomical localization (i.e., temporal). Subgroups IV-a and IV-b have a different and significant distribution of age-class III patients (>61 years, P < .01 Anova-one way).
###end p 76
###begin p 77
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Classification tree derived from the combined measurement of PTEN and MMP9 quantitative expression. At each root, diagnostic classes are divided following the absolute quantification and expressed in femtograms. Probabilities values (P) for the different classes are reported.
###end p 77
###begin p 78
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 275 276 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 338 342 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
Nomogram analysis of PTEN and MMP9 expression within the different WHO grades of malignancy (III, IV) of the astrocytomas specimens. Points and total points axes indicate the points attributed to each variable value and the sum of the points for each variable, respectively. P axes indicate the predicted probability that relates PTEN or MMP9 quantitative expression to each WHO tumor malignancy grade.
###end p 78
###begin p 79
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 345 349 345 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 425 429 425 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 471 472 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 479 480 479 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
###xml 480 486 480 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1.29x</sup>
###xml 488 492 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 507 508 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 516 517 516 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
###xml 517 522 517 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0.50x</sup>
###xml 524 528 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 547 548 547 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 557 558 557 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
###xml 558 564 558 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1.82x</sup>
###xml 566 570 566 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 589 590 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">y</italic>
###xml 598 599 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
###xml 599 604 599 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1.40x</sup>
###xml 200 205 <span type="species:ncbi:9606">human</span>
Statistical trends of PTEN (black dotted line) and MMP9 (grey dotted line) expression in control (C), anaplastic astrocytomas (III) and glioblastoma multiforme (IV) specimens (Panel A), and in normal human astrocytes (NHA), glioma PRT-HU2 (HU2), and U138-MG (U138) cells (Panel B). Trends are calculated using average quantitative expression of PTEN and MMP9, and adopting exponential (Espo) models of prediction as follows: PTEN (C, III, IV average expression samples), y = 2148e-1.29x; MMP9 (C, III, IV), y = 83716e0.50x; PTEN (NHA, HU2, U138), y = 118596e-1.82x; MMP9 (NHA, HU2, U138), y = 42439e1.40x.
###end p 79
###begin p 80
Age, gender, mRNA expression values (in femptograms), and anatomical location of glioblasytoma multiforme samples.
###end p 80
###begin p 81
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
Age, gender, PTEN, and MMP9 expression values (in femtograms), and anatomical location of anaplastic astrocytoma samples.
###end p 81
###begin p 82
Age, gender, mRNA expression values (in femtograms), and anatomical location of normal brain specimens.
###end p 82
###begin p 83
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP9</italic>
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 60 65 <span type="species:ncbi:9606">human</span>
MMP9 and PTEN absolute quantitative expression in different human normal (NHA) and glioma (PRT-HU2 and U138-MG) cell lines. Expression is indicated in femptograms.
###end p 83
###begin p 84
GeneBank accession numbers, PCR primer sequences, and products.
###end p 84

